ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial

Background: Over 13,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, v...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Andrew, Barrans, Sharon, Burton, Cathy, Mercer, Katy, Caddy, Joshua, Chinnery, Fay, Day, Laura, Fernando, Diana, Ardeshna, Kirit, Collins, Graham, Radford, John, Rule, Simon, McMillan, Andrew, Johnson, Peter, Griffiths, Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551525/
https://www.ncbi.nlm.nih.gov/pubmed/33093947
http://dx.doi.org/10.12688/f1000research.22318.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551525/
https://www.ncbi.nlm.nih.gov/pubmed/33093947
http://dx.doi.org/10.12688/f1000research.22318.1

Ejemplares similares